Back Login to subscribe 🔔 Set Alert

LLY Eli Lilly & Co.

Sector: Healthcare
Industry: Drug Manufacturers - General
15 min delay
Today's News Sentiment
Loading...
Upcoming Earnings
Loading...
LLY Fundamental Data
Loading...
Similar Companies
Loading...
LLY Options Chain
Put/Call Ratio
-
-
Expected Move
-
-
Max Pain
-
-
ATM Call Break-even
-
-
ATM Put Break-even
-
-
Loading options…
CALLS
Strike Last Bid Ask Mark IV Volume OI Δ Delta Θ Theta
PUTS
Strike Last Bid Ask Mark IV Volume OI Δ Delta Θ Theta
LLY Insider Transactions
Loading insider data…
LLY News
Date Headline Sentiment
Lilly's EBGLYSS Monotherapy Met Primary And Secondary Endpoints At Week 16 In Its Phase 3B ADtouch Study, Showing Significant And Rapid Improvements In Hand And Foot Skin Clearance, Itch And Pain In Adults And Adolescents With Moderate-To-Severe Hand And Foot Atopic Dermatitis
57.37%
Bill Clinton Sounds Alarm on HIV Funding: ‘Cheaper Medicines Mean Nothing If They Never Reach People’
68.96%
Eli Lilly Announces Detailed Results From TRIUMPH-2; TRIUMPH-2 Participants With Obesity And Type 2 Diabetes Taking Retatrutide 12 Mg Lost An Average Of 49.6 Lbs Over 80 Weeks; Retatrutide 12 Mg Leads To 60.8 Lb Weight Loss In BMI ≥35 Group; To Submit Biologics License Application For Retatrutide In Q1 2027
79.24%
Donald Trump, Cathie Wood Bet on the Same 32 Stocks – Some Might Surprise You
93.19%
Weight Watchers Expands GLP-1 Era Strategy With Google Health
74.36%
Wegovy or Zepbound? Eli Lilly Shows Zepbound Outperforms Wegovy in New Weight Loss Data
79.98%
Eli Lilly Launches Global Push to Expand Weight-Loss and Diabetes Drug Access in Lower Income Countries
87.48%
Eli Lilly Announces Results From New Analysis Showing Zepbound 10 Mg And 15 Mg, Dual GIP And GLP-1 Receptor Agonist, Delivered Greater Weight Loss Than Wegovy HD In Adults With Obesity
80.36%
Eli Lilly's Once-Daily Oral Foundayo 17.2 Mg Outperforms Oral Semaglutide 25 Mg On Weight Loss, A1C At 52 Weeks In Type 2 Diabetes Indirect Comparison Presented At EASD Milan
62.45%
If You Invested $1000 In Eli Lilly Stock 10 Years Ago, You Would Have This Much Today
90.77%